Business Context and Reporting Period
Company: BiondVax Pharmaceuticals Ltd. (Note: Input metadata referenced "Scinai Immunotherapeutics," but the filing text identifies the registrant as BiondVax Pharmaceuticals Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2015
Filing Date: June 1, 2015
Business Overview: BiondVax is a biopharmaceutical company developing M-001, a universal flu vaccine candidate designed for multi-season and multi-strain protection. The company targets three indications: a standalone universal vaccine, a seasonal primer for the elderly, and a pre-pandemic primer.
Key Financial Metrics
All figures in thousands of NIS (New Israeli Shekels) unless otherwise noted. USD conversions provided in the filing are based on an exchange rate of 1 USD = 3.98 NIS.
| Metric | Q1 2015 | Q1 2014 | YTD 2014 |
|---|---|---|---|
| Research & Development Expenses (Net) | 1,172 | 1,467 | 5,492 |
| Marketing, General & Admin Expenses | 650 | 553 | 2,650 |
| Operating Loss | (1,822) | (2,020) | (8,142) |
| Net Loss | (1,864) | (1,967) | (7,764) |
| Net Loss Per Share (Basic & Diluted) | (0.03) | (0.04) | (0.14) |
| Cash and Cash Equivalents (Ending Balance) | 7,397 | 16,018 | 9,612 |
| Total Assets | 16,370 | 23,816 | 18,462 |
| Shareholders' Equity | 14,672 | 22,112 | 16,587 |
| Net Cash Used in Operating Activities | (1,955) | (1,694) | (7,572) |
Material Changes vs. Prior Period
- Revenue/Grant Income: The company recorded NIS 1,195 in revenue from the Office of the Chief Scientist (OCS) and the European Union in Q1 2015, compared to NIS 145 in Q1 2014. This increase partially offset higher gross R&D spending.
- R&D Expenses: Gross R&D spending (excluding grants) increased to NIS 2,367 in Q1 2015 from NIS 1,322 in Q1 2014, primarily driven by expenses related to the BVX-006 clinical trial.
- Administrative Expenses: Marketing, general, and administrative expenses increased by approximately 17% year-over-year due to higher legal and business development costs.
- Liquidity: Cash and cash equivalents decreased significantly from NIS 16,018 at the end of Q1 2014 to NIS 7,397 at the end of Q1 2015. This decline is attributed to R&D expenditures and costs associated with the U.S. IPO.
- Equity: Shareholders' equity decreased from NIS 22,112 in Q1 2014 to NIS 14,672 in Q1 2015, reflecting the accumulation of net losses.
Guidance, Outlook, and Significant Events
- U.S. Initial Public Offering (IPO): On May 15, 2015, the company closed its U.S. IPO, selling 1,910,000 American Depositary Shares (ADSs) and warrants at $5.00 per ADS. Gross proceeds were approximately $9.57 million. The underwriter partially exercised an option to purchase an additional 128,000 warrants.
- Liquidity Outlook: Management stated that following the May 2015 capital raise, financial resources are sufficient to fund operations for at least 20 months.
- Executive Compensation Changes: In May 2015, the Board approved a salary increase for the CEO (Dr. Ron Babecoff) from NIS 52,500 to NIS 80,000 per month and a salary increase for the Chief Scientific Officer. Additionally, options totaling 3,780,000 shares were approved for employees and officers, vesting over three years.
- Board Changes: Professor Benad Goldwasser resigned as a director in January 2015. Rami Epstein retired from the Board and committees in May 2015. Michal Marom Brikman was appointed as an independent director with accounting expertise in May 2015.
- Seasonality: While traditional flu vaccines are seasonal, the company believes its universal vaccine (M-001) will not be subject to the same seasonality if approved as a standalone or pandemic primer. However, sales as a seasonal primer for the elderly are expected to occur during influenza season.
Investor Verification Checklist
- Capital Runway: Verify the actual net proceeds from the May 2015 IPO after deducting underwriting discounts and offering expenses to confirm the "20-month" runway estimate.
- Clinical Trial Progress: Confirm the status and cost trajectory of the BVX-006 clinical trial, which was the primary driver of increased R&D expenses.
- Grant Sustainability: Assess the reliability of future funding from the Office of the Chief Scientist and the European Union, which significantly reduced the reported net loss in Q1 2015.
- Dilution Impact: Review the terms of the newly granted options (3.78 million shares) and the IPO warrants to understand potential future dilution to existing shareholders.
- Regulatory Pathway: Verify the current status of regulatory filings for the three intended indications (Standalone, Elderly Primer, Pandemic Primer).